论文部分内容阅读
目的观察门冬胰岛素30治疗2型糖尿病的疗效及安全性。方法60例口服降糖药物效果差的2型糖尿病患者随机分为门冬胰岛素组和Novolin 30R组,观察12周,比较2组治疗前后的血糖控制情况、糖化血红蛋白、空腹C肽、餐后2 h C肽、体重、胰岛素用量、低血糖发生率的变化。结果两组均能有效的控制血糖的作用(P<0.05),在控制空腹血糖方面无明显差异,门冬胰岛素30组的有更好的控制早餐、晚餐后血糖得到明显改善,低血糖的发生率减少,差异有统计学意义(P<0.05),所需胰岛素量较少,但差异无统计学意义(P>0.05)。结论每天2次注射门冬胰岛素30较诺和灵30组能更好的控制餐后血糖,且低血糖发生率低。
Objective To observe the efficacy and safety of insulin aspart 30 in type 2 diabetes mellitus. Methods Sixty patients with type 2 diabetes who had poor oral glucose tolerance were randomly divided into insulin aspart group and Novolin 30R group for 12 weeks. The blood glucose control, glycosylated hemoglobin, fasting C-peptide, postprandial 2 h C peptide, body weight, insulin dosage, the incidence of hypoglycemia. Results Both groups could effectively control the effect of blood sugar (P <0.05), and there was no significant difference in controlling fasting blood glucose. Aspartic insulin 30 had better control of breakfast, blood glucose was significantly improved after dinner, hypoglycemia The rate of decrease was statistically significant (P <0.05), the required amount of insulin less, but the difference was not statistically significant (P> 0.05). CONCLUSION: Aspirin 30 is better than noradren 30 twice daily in controlling postprandial blood glucose, and the incidence of hypoglycemia is low.